Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans

benzinga.com/news/health-care/25/11/48904205/zymeworks-jazz-pharmaceuticals-stocks-climb-on-robust-gastroesophageal-trial-outcomes-and-upcomi

Zymeworks Inc. (NASDAQ:ZYME) stock is surging on Monday, with a session volume of 2.17 million, compared to an average volume of 728.75K, according to Benzinga Pro.
Zymework, along with its partners, Jazz Pharmaceuticals Inc. (NASDAQ:JAZZ) and BeOne Medicines Inc. (NASDAQ:ONC), announced…

This story appeared on benzinga.com, 2025-11-17 17:09:52.
The Entire Business World on a Single Page. Free to Use →